Implications of Genetic Testing in Dilated Cardiomyopathy
- 1 October 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Genomic and Precision Medicine
- Vol. 13 (5), 476-487
- https://doi.org/10.1161/CIRCGEN.120.003031
Abstract
Background: Genetic analysis is a first-tier test in dilated cardiomyopathy (DCM). Electrical phenotypes are common in genetic DCM, but their exact contribution to the clinical course and outcome is unknown. We determined the prevalence of pathogenic gene variants in a large unselected DCM population and determined the role of electrical phenotypes in association with outcome. Methods: This study included 689 patients with DCM from the Maastricht Cardiomyopathy Registry, undergoing genetic evaluation using a 48 cardiomyopathy-associated gene-panel, echocardiography, endomyocardial biopsies, and Holter monitoring. Upon detection of a pathogenic variant in a patient with DCM, familial segregation was performed. Outcome was defined as cardiovascular death, heart transplantation, heart failure hospitalization, and/or occurrence of life-threatening arrhythmias. Results: A (likely) pathogenic gene variant was found in 19% of patients, varying from 36% in familial to 13% in nonfamilial DCM. Family segregation analysis showed familial disease in 46% of patients with DCM who were initially deemed nonfamilial by history. Overall, 18% of patients with a nongenetic risk factor had a pathogenic gene variant. Almost all pathogenic gene variants occurred in just 12 genes previously shown to have robust disease association with DCM. Genetic DCM was independently associated with electrical phenotypes such as atrial fibrillation, nonsustained ventricular tachycardia, and atrioventricular block and inversely correlated with the presence of a left bundle branch block (P<0.01). After a median follow-up of 4 years, event-free survival was reduced in genetic versus patients with nongenetic DCM (P=0.01). This effect on outcome was mediated by the associated electrical phenotypes of genetic DCM (P<0.001). Conclusions: One in 5 patients with an established nongenetic risk factor or a nonfamilial disease still carries a pathogenic gene variant. Genetic DCM is characterized by a profile of electrical phenotypes (atrial fibrillation, nonsustained ventricular tachycardia, and atrioventricular block), which carries increased risk for adverse outcomes. Based on these findings, we envisage a broader role for genetic testing in DCM.Keywords
This publication has 30 references indexed in Scilit:
- Multicenter Experience With Catheter Ablation for Ventricular Tachycardia in Lamin A/C CardiomyopathyCirculation: Arrhythmia and Electrophysiology, 2016
- The Diagnosis and Evaluation of Dilated CardiomyopathyJournal of the American College of Cardiology, 2016
- Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseasesEuropean Heart Journal, 2016
- Prognostic Relevance of Gene-Environment Interactions in Patients With Dilated CardiomyopathyJournal of the American College of Cardiology, 2015
- Genetics and genotype–phenotype correlations in Finnish patients with dilated cardiomyopathyEuropean Heart Journal, 2015
- Atlas of the clinical genetics of human dilated cardiomyopathyEuropean Heart Journal, 2014
- The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencingGenetics in Medicine, 2014
- The MOGE(S) Classification of Cardiomyopathy for CliniciansJournal of the American College of Cardiology, 2014
- Where Genome Meets Phenome: Rationale for Integrating Genetic and Protein Biomarkers in the Diagnosis and Management of Dilated Cardiomyopathy and Heart FailureJournal of the American College of Cardiology, 2012
- Underlying Causes and Long-Term Survival in Patients with Initially Unexplained CardiomyopathyNew England Journal of Medicine, 2000